Unusual market activity is often the first sign that big changes are coming to a stock. Professional traders and large ...

Wednesday, January 14, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie ...

The Trump administration has finalized a deal with drugmaker AbbVie to cut the cost of certain medicines, marking the latest pact as part of its "Most Favored Nation" pricing initiative.

AbbVie commits to lowering Medicaid drug prices and investing $100 billion in US R&D and capital investments over the next decade. The TrumpRx program will expand direct-to-patient offerings, ...

As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on ...

AbbVie has also pledged to participate in TrumpRx and offer many of its products, including Humira, on a direct-to-patient ...

Though far from the first large drugmaker to strike a pricing deal with the Trump administration, AbbVie’s new accord is ...

Hold iShares U.S. Healthcare ETF (IYH): top holdings face GLP-1 risks, patent cliffs and high valuations. Read here for an ...

AbbVie (ABBV) inks Trump deal to cut Medicaid drug prices, expand TrumpRx discounts, and invest $100B in U.S. R&D for tariff relief.

AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...

Britta DeVore is a Senior Author for Collider who has been known to dabble with Reality News as well. When she isn't sitting behind her laptop bringing readers her hot takes on upcoming projects or ...